Crd3874-si
Phase 1
Crd3874-si is one of 52 therapeutic programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Xospata
AstellasPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Nexavar
BayerPhase 3
Cellcept
RochePhase 3
Busulfex
Akero TherapeuticsPhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Crd3874-si. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]